Wells Fargo & Company MN Has $5.03 Million Stake in DaVita Inc. (NYSE:DVA)

Wells Fargo & Company MN trimmed its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 38.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,607 shares of the company's stock after selling 20,692 shares during the quarter. Wells Fargo & Company MN's holdings in DaVita were worth $5,026,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in DVA. JPMorgan Chase & Co. lifted its holdings in DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after purchasing an additional 92,014 shares during the period. Amundi boosted its stake in DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after purchasing an additional 240,126 shares in the last quarter. KBC Group NV lifted its holdings in shares of DaVita by 0.8% in the fourth quarter. KBC Group NV now owns 316,155 shares of the company's stock valued at $47,281,000 after buying an additional 2,636 shares during the period. Nordea Investment Management AB grew its holdings in DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock worth $39,712,000 after acquiring an additional 12,339 shares during the period. Finally, California Public Employees Retirement System boosted its position in shares of DaVita by 75.1% during the 4th quarter. California Public Employees Retirement System now owns 196,788 shares of the company's stock valued at $29,430,000 after purchasing an additional 84,375 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Up 3.0 %

NYSE DVA traded up $4.11 on Wednesday, reaching $139.08. The stock had a trading volume of 917,628 shares, compared to its average volume of 837,496. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 1 year low of $130.96 and a 1 year high of $179.60. The business has a 50 day moving average price of $147.51 and a 200 day moving average price of $155.64. The company has a market capitalization of $11.13 billion, a price-to-earnings ratio of 12.95, a P/E/G ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on DVA. Barclays upped their price target on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Thursday, April 10th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research report on Friday, February 21st. Finally, Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, DaVita presently has an average rating of "Hold" and a consensus price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.